





Central pontine myelinolysis secondary to glycemic variability in type 1 diabetes: a case report and a systematic review of the literature

Stefania Di Agostino¹, Arianna A.C. Costanzo¹, Pietro Andreone² , Mauro Maurantonio^{2*} 

¹Division of Metabolic Internal Medicine, University of Modena and Reggio Emilia, 41126 Modena, Italy

²Department of Internal Medicine, General, Emergency and Post-Acute, Division of Metabolic Internal Medicine, University Hospital of Modena, 41126 Modena, Italy

***Correspondence:** Mauro Maurantonio, Department of Internal Medicine, General, Emergency and Post-Acute, Division of Metabolic Internal Medicine, University Hospital of Modena, Azienda Ospedaliero-Universitaria di Modena, v. P. Giardini 1355, 41126 Modena, Italy. maurantonio.mauro@aou.mo.it

Academic Editor: Lindsay A. Farrer, Boston University School of Medicine, USA

Received: May 8, 2021 **Accepted:** June 24, 2021 **Published:** August 31, 2021

Cite this article: Di Agostino S, Costanzo AAC, Andreone P, Maurantonio M. Central pontine myelinolysis secondary to glycemic variability in type 1 diabetes: a case report and a systematic review of the literature. *Explor Med.* 2021;2:324-32. <https://doi.org/10.37349/emed.2021.00050>

Abstract

Central pontine myelinolysis (CPM) is a rare manifestation of osmotic demyelination syndrome (ODS) which involves the pons and causes significant morbidity and mortality. CPM usually occurs in the setting of rapid correction of severe chronic hyponatremia. A rare case of CPM due to hyperglycemia in a 27-year-old man with type 1 diabetes is reported. During the patient's hospitalization, his plasma glucose level showed a wide variability ranging from 38 mg/dL to 530 mg/dL; while plasma sodium level was constantly normal. At computed tomography (CT) scans, areas of hypodensity with a hyperdense ring were identified in the anterior part of the pons. At magnetic resonance imaging (MRI) scan, pontine abnormalities compatible with CPM were observed. According to laboratory tests, we concluded that CPM resulted from rapid and wide shifts in osmolar gradient owing to variability in plasma glucose levels. While universally recognized in several clinical settings, CPM is rarely observed in diabetic patients. Our report supports the notion that hyperosmolarity per se plays a key role in the pathogenesis of CPM, which may occur independently of sodium abnormalities.

Keywords

Central pontine myelinolysis, hyponatremia, hyperglycemia, diabetes mellitus

Introduction

Central pontine myelinolysis (CPM) is a rare manifestation of osmotic demyelination syndrome (ODS) which involves the pons. Especially in case of either malnutrition or alcoholic hepatitis, the most common cause of CPM is rapid correction of hyponatremia, which clinically is heralded by encephalopathy [1, 2]. In patients with diabetes mellitus, clinical conditions of hyperglycemia, hypovolemia, metabolic acidosis, and electrolyte

© The Author(s) 2021. This is an Open Access article licensed under a Creative Commons Attribution 4.0 International License (<https://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.



imbalance require aggressive schedules of parental hydration and intravenous insulin therapy to correct hyperosmolality state. However, such intensive management can also cause major shifts in plasma osmolality associated with rapid rises in plasma sodium concentrations which happen as plasma glucose values rapidly decline. CPM occurring in the context of these clinical manifestations has been reported in only few cases. We report on an unusual case of CPM due to hyperglycemia and normal serum sodium in a patient with type 1 diabetes (T1D); moreover, we extensively reviewed the pertinent literature on the pathogenesis of CPM.

Case report

A 27-year-old man with autoimmune anti-glutamic acid decarboxylase (anti-GAD) positive T1D was admitted to our medical ward on the grounds of systemic weakness, sensory loss at the lower extremities, throbbing headache, dizziness, photophobia, and chronic, unexplained diarrhea.

Our patient was diagnosed with autoimmune T1D at the age of 13 with microvascular complications: retinopathy submitted to laser photocoagulation and neuropathy treated with gabapentin and duloxetine. Moreover, owing to inadequate compliance to therapy he had suffered from some episodes of hypoglycemic coma a few years earlier. Furthermore, he had chronic unexplained diarrhea with blood, fecal and histologic tests negative for infectious causes and celiac disease. He also reported previous diagnosis of gastroesophageal reflux disease and was hospitalized owing to acid reflux, heartburn, dyspnea, and chest pain treated with proton pump inhibitors. Our psychiatric consultant identified depression reactive to social and familiar deprivation given that the patient lived in Italy but his mother and his wife lived in Morocco.

At time of admission, he presented sensory loss at the lower right extremity associated with impairment of strength, mild-severe headache, nausea, dizziness, and photophobia, without vomiting. Strength, sensitivity, muscle tone, and reflexes were normal in the upper limbs. He presented leg weakness with deficient muscle tone: grade 4 hypostenia at right iliopsoas, grade 2 hypostenia of anterior tibial muscle, and grade 4 hypostenia of peroneous muscle. Plantar flexor reflexes were poorly elicitable.

His plasma glucose was 217 mg/dL, with glycosuria 500 mg/dL and HbA1c 115 mmol/mol. Serum sodium was 141 mEq/L, and hepatic and renal function tests were normal. Urinary C-peptide was below to normal range, suggestive of a beta-cell pancreatic insufficiency; albuminuria was present (Table 1).

Table 1. Blood and urine tests in decompensated diabetes and pancreatic insufficiency

Parameters	Patient value	Reference range
HbA1c	115 mmol/mol	20-38 mmol/mol
Glycosuria	500 mg/dL	< 180 mg/dL
Urinary C-peptide	< 0.1 ng/mL	1.1-4.4 ng/mL
Urinary C-peptide 24 h	undetectable	24-207 microg/24 h
Albuminuria	> 300 mg/g	< 30 mg/24 h
Diuresis	1700 mL/24 h	not applicable

Electromyography was compatible with moderate peripheral sensitive and motor axonal polyneuropathy. Analysis of cerebral spinal fluid showed high total protein and immunoglobulin-G (IgG) oligoclonal band at protein electrophoresis; the search for Borrelia and other infectious agents was negative. Autoimmune diseases, Whipple disease, gangliosidosis, and cancer were all ruled out. To identify the cause of chronic diarrhea, the patient underwent screening for coeliac disease, autoimmune disease, infectious gastroenteritides (in particular *Salmonella species*, *Shigella*, and *Campylobacter*), and inflammatory bowel diseases. Given that all these tests were negative, diarrhea was attributed to vegetative neuropathy.

Magnetic resonance imaging (MRI) angiography (Angio-MRI) scanning disclosed regular signal in the vascular system at the level of Willis polygon while MRI scan of brain showed abnormal signal centrally in the pons: hyperintense pontine lesions on long repetition time (TR) sequence, hypointense on T1-weighted scans, with increased diffusion coefficient, with an ovalar morphology and a cranio-caudal diameter of 14 mm with transverse fibers of the pons involved, without abnormalities in the peripheral part of the pons or mass

effect. Moreover, imaging showed extensive atrophy both in the basilar area and the tegmentum of pons, and dilated fourth ventricle (Figure 1).




Figure 1. MRI scan of brain: signal abnormalities in the central part of the pons. Hyper-intense pontine lesions on long TR sequence (on left), hypo-intense on T1 scans (on right)

Our patient was diagnosed with CPM. During the hospitalization, his plasma glucose showed a wide variability ranging from 38 mg/dL to 530 mg/dL while sodium plasma levels were always normal (Figure 2).




Figure 2. Glycemic variability in the patient with decompensated T1D

With appropriate insulin therapy, glycemic stabilization was achieved which allowed full recovery of general and neurological conditions at discharge.

Discussion

Literature review about CPM: common etiologies and typical presentation

We systematically searched PubMed database using the following keywords “Central Pontine Myelinolysis”, “Osmotic demyelination syndrome”, “Diabetes Mellitus” and “Hyperglycemia”. Studies that evaluated the effects of hyponatremia, hypernatremia or normonatremia, and hyperglycemia on CPM were included. Criteria for exclusion: studies that considered pediatric and/or geriatric and/or Japanese population and studies that described ODS due to other neurological etiologies (Figure 3).




Figure 3. Strategy research in the systematic review

ODS is an uncommon neurological disorder caused by damage to the myelin sheath of nerve fibers. CPM is the typical presentation, reflecting greater susceptibility of pontine white matter tracts, consisting of focal, bilaterally symmetric region of myelin destruction; however, extra-pontine involvement (extra-pontine myelinolysis or EPM) is common [1, 2].

CPM was first described in 1959 by Adams and Victor who reported on four patients with quadriplegia and pseudo-bulbar palsy, three of these were chronic alcoholics and all were malnourished [3].

As is shown in Table 2, CPM can occur in a variety of clinical settings [1-24].

Table 2. Systematic review—CPM in a variety of clinical settings

CPM etiology	Reported in
Alcohol and malnutrition	Adams RD (1959) [3]
	Case report on four malnourished patients
“Any relatively hypertonic insult”	McKee AC (1988) [4]
	Retrospective study on 3,528 patients submitted to general autopsy
Rapid correction of hyponatremia	Brown WD (2000) [1]
	Review article
Severe hyperemesis gravidarum-induced hyponatremia	Lee IW (2010) [5]
	Case report on pregnant woman

Table 2. Systematic review—CPM in a variety of clinical settings (*continued*)

CPM etiology	Reported in
Hypophosphatemia	Qadir F (2005) [6] Case report on a young lady with prolonged febrile illness and severe hypophosphatemia
Hypokaliemia	Shintani M (2016) [7] Case report on a 43-year-old diabetic man with nephrotic syndrome
Hypokalemic in nephrogenic diabetes insipidus	Davenport C (2010) [8] Case report on a 63-year-old man with nephrogenic diabetes insipidus
Liver transplantation	Singh N (1994) [9] Clinical review of a subgroup of patients after liver transplantation
Lithium toxicity	Fabisiak DB (2002) [10] Case report on patient in lithium therapy for bipolar disorder
Lymphoma	Doni E (2016) [11] Case report on patient with diffuse large-B cell lymphoma
Acquired metabolic encephalopathies	Sharma P (2009) [12] A pictorially review of the more classic MRI features of several acute toxic and acquired metabolic encephalopathies
Intravenous sodium bicarbonate therapy	Chang KY (2014) [13] Case report on a 40-year-old woman with a bicarbonate deficit
Hyperglycemic with rebound hyponatremia	O'Malley G (2008) [14] Case report on a 49-year-old woman with hyperglycemic hyperosmolar state
Hyperglycemic with normal natremia	Donnelly H (2016) [2] Burns JD (2013) [15] Guerrero WR (2013) [16] Hirosawa (2018) [17] Corps Fernández D (2017) [18] Fasano A (2018) [19] Case reports on patients with hyperglycemia
Binge eating attack induced hyperglycemia in the absent of a relevant hyponatremia	Pliquett RU (2018) [20] Case report on a type 2 diabetes patient with hyperglycemia after a binge-eating attack
Chronic kidney disease	Talluri S (2017) [21] Case report on a patient with chronic kidney disease and hyperosmolar hyperglycemia
Fluctuating hyperglycemia in patient treated with interferon and insulin therapy	Gourine M (2016) [22] Case report on a diabetic young patient chronic hepatitis as predisposing factor for rapid changes in osmolality
Acute hypoglycemia	Madey JJ (2013) [23] Case report in diabetic patient treated with levofloxacin Purucker E (2000) [24] Case report in patient with myocardial infarction following severe hypoglycemia

CPM, most often reported in association with rapid correction of severe chronic hyponatremia, has also been described associated with other electrolyte derangements such as hypophosphatemia, hypokalemia as well as in the setting of liver transplantation and lithium toxicity [6, 7, 9, 10].

In chronic hyponatremia, electrolytes are lost from intracellular space flowing into cerebrospinal fluid over a few days during which brain cells become isotonic to the extracellular fluid to maintain cell volume through a process called “cerebral adaptation”. As a result, given that they can neither synthesize nor transport

osmotic substrates at such rapid rates (which leads to osmotic demyelination), oligodendrocytes will shrink up as a consequence of cell volume loss during rapid correction of tonicity [25].

Clinical manifestations are variable: various degrees of encephalopathy are commonly observed however either totally asymptomatic or mildly symptomatic cases can also occur. Typically patients with ODS present with parkinsonism, quadriparesis, “locked-in” syndrome, coma, bulbar palsy, or, less frequently, with dysphagia, dysarthria, facial paresis, ataxia, nystagmus, tremor, lethargy, confusion, behavioral disturbances, and/or disorientation [26, 27].

In the past, brainstem auditory evoked potentials were used, but modern imaging has superseded its use, and brain MRI is the current accepted standard diagnostic technique because of a greater sensitivity and a superior capacity for the demonstration of the lesions of EPM, than CT. At MRI, hyperintense lesions on T2 weighted, and hypointense lesions on T1 weighted images are suggestive for CPM [25].

Other than supportive treatment, there is no effective treatment for CPM. Supportive treatment should be provided to all patients for at least 6-8 weeks before making any conclusions regarding irreversibility of disease. In cases where CPM is caused by rapid correction of severe chronic hyponatremia lowering serum sodium may be beneficial if initiated early. In literature there is some evidence supporting the beneficial role of plasma exchange techniques that allow removal from blood circulation of myelin toxic substances. Conversely, the use of steroids and intravenous immunoglobulins is not supported by evidence [25].

CPM owing to uncommon etiology

McKee et al. [4] have suggested that myelinolysis can result from any “relatively hypertonic insult”. These authors have speculated that CPM can result from any circumstances wherein serum and extracellular space become hypertonic faster than brain cells can compensate.

Reports of ODS associated with hyperglycemic hyperosmolar state with rebound hyponatremia have been published [14]. Over the last few years, CPM has also been reported in diabetic patients exhibiting deranged metabolic control even in the absence of electrolyte disturbances [2, 15].

In 2015, Saini et al. [28] reported on a case of CPM secondary to hyperglycemia per se rather than secondary to its treatment. The patient presented with ataxia and pseudobulbar manifestations and followed a sub-acute course over a two-week time.

Hyperglycemia, by leading to an increased plasma osmolality, has been blamed to cause pontine demyelination both in type-2 diabetes and in a T1D patient [15, 28, 29]. This complication has also been described in a patient with latent autoimmunity diabetes displaying significant glucose fluctuations [30].

Although the possible pathogenic mechanisms responsible for development of CPM in patients with diabetes are still a matter of debate, a few hypotheses have been proposed in earlier studies. In patients with poorly controlled diabetes, hyperosmolarity resulting from increased blood glucose with greater osmolar shifts might cause brain edema. An explanation might be that in chronically uncontrolled diabetes, osmotic stress induces protein damage and aggregation within brain oligodendrocytes.

More specifically, it has been postulated that serum hyperosmolarity induces the release of nitric oxide and inflammatory mediators and this may damage tight junctions. Furthermore, toxic substances released by damaged endothelial cells may injure oligodendrocytes [31].

In the setting of hyperosmolar hyperglycemia, several theories have been proposed to explain the pathogenesis of osmotic demyelination: rapid changes in osmolality associated with the fluctuations in serum glucose, subacute changes in brain cells secondary to hyperglycemia, and hypertonic insult associated with hyperglycemia [31].

Moreover, risk factors for CPM in diabetics include concurrent diabetic nephropathy requiring dialysis, infection with hepatitis C virus, and arterial hypertension [32].

The only treatment for non-sodium-dependent osmotic demyelination is supportive care [27].

In this case report, diagnosis of CPM was based on the evidence of injury to central pons, which was clinically compatible with myelinolysis due to metabolic derangement. Generally, CPM is caused by osmotic

demyelination due to rapid correction of hyperosmolarity in hyponatremia. Only in very rare cases does this condition occur in patients with diabetes and normal serum sodium concentration: in these, it would seem plausibly caused by the hyperosmotic effects of glucose which carries oligodendrocyte fluids into the extracellular compartment. In our case, this effect was also presumably facilitated by concurrent dehydration caused by chronic diarrhea.

In literature, CPM has been attributed to sudden, severe, and sustained hyperglycemia, especially when another risk factor is present such as malnutrition, alcohol abuse, chronic diseases, and liver cirrhosis, which are all listed as risk factors for CPM. Reports of hypoglycemic-induced CPM/ODS are rare; glucose deprivation can lead to cytotoxic edema secondary to the failure of ion pumps in the cell membrane that manifests itself with MRI changes typical of CPM [24]. Furthermore, over-treatment resulting in hyperglycemia will activate the nicotinamide adenine dinucleotide phosphate (NADPH) pathway in neurons, causing cytotoxic oxidative stress. Our literature research shows the possible involvement of drugs, although there is no often a causal correlation with CPM/ODS; however, the hypothesis of drug influence should be kept in mind in unexplained neurological manifestation suggestive for CPM [10, 22]. For example, it is known that fluoroquinolones can cause or exacerbate hypoglycemia as consequence of direct stimulation of insulin secretion from the β -cells of the pancreas and typically occurs 4-6 days after the start of antibiotic therapy: this can play a crucial role in diabetic patients [24].

There are only few other similar published cases of CPM complicating the management of the correction of the variability of glucose levels in patient with diabetes. Conversely, there are more cases of CPM due to other predisposing factors (either chronic comorbidities or drugs). Despite the variability of etiologies, many patients were diabetics and this might highlight the close link of CPM with diabetes. CPM should always be considered in the differential diagnosis of neurological manifestations in patients with diabetes.

In conclusion, CPM, a potentially fatal condition, follows a favorable course provided that it is promptly recognized and managed. Our case suggests that, in diabetic patients presenting with signs and symptoms of CPM, recent episodes of decompensated glucose control as well as a large variability of glucose serum levels must both be taken into consideration to reduce the risk of brain damage. In conclusion, it is necessary to monitor neurological and cognitive status in patients with diabetes and/or other clinical conditions in which both an inappropriately rapid correction of osmolarity and any hypertonic insult in normal osmolarity status could potentially cause CPM.

Abbreviations

CPM: central pontine myelinolysis

MRI: magnetic resonance imaging

ODS: osmotic demyelination syndrome

T1D: type-1 diabetes

Declarations

Author contributions

SDA wrote the first draft of the manuscript; SDA and AACC wrote section of the manuscript; SDA, PA, and MM contributed to manuscript revision; all authors read and approved the submitted version.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

The consent to participate in the description of the case report is informed.

Consent to publication

Consent to publication of the privacy issues has been obtained.

Availability of data and materials

Not applicable.

Funding

Not applicable.

Copyright

© The Author(s) 2021.

References

1. Brown WD. Osmotic demyelination disorders: central pontine and extrapontine myelinolysis. *Curr Opin Neurol*. 2000;13:691-7.
2. Donnelly H, Connor S, Quirk J. Central pontine myelinolysis secondary to hyperglycaemia. *Pract Neurol*. 2016;16:493-5.
3. Adams RD, Victor M, Mancall EL. Central pontine myelinolysis: a hitherto undescribed disease occurring in alcoholic and malnourished patients. *AMA Arch Neurol Psychiatry*. 1959;81:154-72.
4. McKee AC, Winkelman MD, Banker BQ. Central pontine myelinolysis in severely burned patients: relationship to serum hyperosmolality. *Neurology*. 1988;38:1211-7.
5. Lee IW, Su MT, Kuo PL, Chang CM. Gestational diabetes and central pontine myelinolysis with quadriplegia: a case report. *J Matern Fetal Neonatal Med*. 2010;23:728-31.
6. Qadir F, Hasan A, Masood M. Extra pontine myelinolysis associated with hypophosphatemia. *J Pak Med Assoc*. 2005;55:254-6.
7. Shintani M, Yamashita M, Nakano A, Aotani D, Maeda K, Yamamoto T, et al. Central pontine and extrapontine myelinolysis associated with type 2 diabetic patient with hypokalemia. *Diabetes Res Clin Pract*. 2005;68:75-80.
8. Davenport C, Liew A, Vic Lau P, Smith D, Thompson CJ, Kearns G, et al. Central pontine myelinolysis secondary to hypokalaemic nephrogenic diabetes insipidus. *Ann Clin Biochem*. 2010;47:86-9.
9. Singh N, Yu VL, Gayowski T. Central nervous system lesions in adult liver transplant recipients: clinical review with implications for management. *Medicine (Baltimore)*. 1994;73:110-8.
10. Fabisiak DB, Murray GB, Stern TA. Central pontine myelinolysis manifested by temporary blindness: a possible complication of lithium toxicity. *Ann Clin Psychiatry*. 2002;14:247-51.
11. Doni E, Tremolizzo L, Patassini M, Pioltelli PE, Ferrarese C, Appollonio I. Asymptomatic central pontine myelinolysis without hyponatremia in diffuse large B cell lymphoma. *Neurol Sci*. 2016;37:2035-7.
12. Sharma P, Eesa M, Scott JN. Toxic and acquired metabolic encephalopathies: MRI appearance. *AJR Am J Roentgenol*. 2009;193:879-86.
13. Chang KY, Lee IH, Kim GJ, Cho K, Park HS, Kim HW. Plasma exchange successfully treats central pontine myelinolysis after acute hypernatremia from intravenous sodium bicarbonate therapy. *BMC Nephrol*. 2014;15:56.
14. O'Malley G, Moran C, Draman MS, King T, Smith D, Thompson CJ, et al. Central pontine myelinolysis complicating treatment of the hyperglycaemic hyperosmolar state. *Ann Clin Biochem*. 2008;45:440-3.
15. Burns JD, Kosa SC, Wijdicks EF. Central pontine myelinolysis in a patient with hyperosmolar hyperglycemia and consistently normal serum sodium. *Neurocrit Care*. 2009;11:251-4.
16. Guerrero WR, Dababneh H, Nadeau SE. Hemiparesis, encephalopathy, and extrapontine osmotic myelinolysis in the setting of hyperosmolar hyperglycemia. *J Clin Neurosci*. 2013;20:894-6.

17. Hirosawa T, Shimizu T. Osmotic demyelination syndrome due to hyperosmolar hyperglycemia. *Cleve Clin J Med*. 2008;85:511-3.
18. Corps Fernández D, Terrero Carpio R, Escolar Escamilla E, Pinel González A. Mielinólisis central pontina de curso subagudo secundario a hiperglucemias. *Neurología*. 2020;35:211-3.
19. Fasano A, Cavallieri F, Mandrioli J, Chiari A, Nichelli P. Central pontine myelinolysis and poorly controlled diabetes: MRI's hints for pathogenesis. *Neurol Sci*. 2018;39:193-5.
20. Pliquet RU, Noll A, Ibe R, Katz A, Ackmann C, Schreiber A, et al. Hyperglycemia-related central pontine demyelination after a binge-eating attack in a patient with type-2 diabetes: a case report. *BMC Endocr Disord*. 2018;18:18.
21. Talluri S, Charumathi R, Khan M, Kissell K. Atypical presentation of central pontine myelinolysis in hyperglycemia. *Endocrinol Diabetes Metab Case Rep*. 2017;2017:17-0064.
22. Gourine M, Mostefa-Kara A, Saadi S, Arrar M, Cherrak A. Central pontine myelinolysis in a type 1 diabetes patient with chronic hepatitis. *Rev Neurol (Paris)*. 2018;174:66-7.
23. Madey JJ, Hannah JA, Lazaridis C. Central pontine myelinolysis following acute hypoglycemia. *Clin Neurol Neurosurg*. 2013;115:2299-300.
24. Purucker E, Nguyen HN, Lammert F, Koch A, Matern S. Central pontine myelinolysis and myocardial infarction following severe hypoglycemia. *Intensive Care Med*. 2000;26:1406-7.
25. Martin RJ. Central pontine and extrapontine myelinolysis: the osmotic demyelination syndromes. *J Neurol Neurosurg Psychiatry*. 2004;75 Suppl 3:iii22-8.
26. de Souza A. Movement disorders and the osmotic demyelination syndrome. *Parkinsonism Relat Disord*. 2013;19:709-16.
27. King JD, Rosner MH. Osmotic demyelination syndrome. *Am J Med Sci*. 2010;339:561-7.
28. Saini M, Mamaug MJ, Singh R. Central pontine myelinolysis: a rare presentation secondary to hyperglycaemia. *Singapore Med J*. 2015;56:e71-3.
29. Sharma C, Kumawat BL, Panchal M, Shah M. Osmotic demyelination syndrome in type 1 diabetes in the absence of dyselectrolytaemia: an overlooked complication? *BMJ Case Rep*. 2017;2017:bcr2016219148.
30. Tajitsu M, Yamada T, Cao X, Fukui A, Nagai J, Yambe Y, et al. Osmotic demyelination syndrome complicating diabetes with anti-glutamic acid decarboxylase antibodies and Graves' disease: a case report. *J Diabetes Investig*. 2016;7:130-1.
31. Rodríguez-Velver KV, Soto-García AJ, Zapata-Rivera MA, Montes-Villarreal J, Villarreal-Pérez JZ, Rodríguez-Gutiérrez R. Osmotic demyelination syndrome as the initial manifestation of a hyperosmolar hyperglycemic state. *Case Rep Neurol Med*. 2014;2014:652523.
32. Ichikawa H, Murakami H, Katoh H, Hieda S, Kawamura M. Central pontine lesions observed with MRI in four diabetic patients. *Intern Med*. 2008;47:1425-30.